Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00083889 · ClinicalTrials.gov registry record · Phase 3

SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma

A Phase 3 study of Carcinoma, Renal Cell, sponsored by Pfizer.

Completed
Registry status
Phase 3
Development phase
750
Enrollment target
20
Study locations

NCT00083889 is a Phase 3 study of Carcinoma, Renal Cell that has completed, run by Pfizer. The registered enrollment target is 750 participants, above the 261-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (187% higher). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00083889, a Phase 3 study of Carcinoma, Renal Cell, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 3
Development phase
750 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).

Conditions Studied

Carcinoma, Renal Cell

Interventions

  • DRUG SU011248
  • DRUG Interferon-alfa

Study Locations (20)

California

  • Pfizer Investigational Site - La Jolla
  • Pfizer Investigational Site - La Jolla
  • Pfizer Investigational Site - Los Angeles
  • Pfizer Investigational Site - San Diego
  • Pfizer Investigational Site - San Francisco

Connecticut

  • Pfizer Investigational Site - New Haven
  • Pfizer Investigational Site - New Haven
  • Pfizer Investigational Site - New Haven

Florida

  • Pfizer Investigational Site - Miami
  • Pfizer Investigational Site - Miami
  • Pfizer Investigational Site - Tampa

Illinois

  • Pfizer Investigational Site - Chicago
  • Pfizer Investigational Site - Maywood

Kansas

  • Pfizer Investigational Site - Kansas City
  • Pfizer Investigational Site - Overland Park

Louisiana

  • Pfizer Investigational Site - Covington
  • Pfizer Investigational Site - Metairie

Arkansas

  • Pfizer Investigational Site - Jonesboro

Colorado

  • Pfizer Investigational Site - Aurora

Trial Details

FieldValue
Enrollment Target 750 participants
Start Date 2004-08
Est. Completion 2008-09
Phase Phase 3

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00083889

The ClinicalTrials.gov registry entry for NCT00083889 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 750 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 261-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (187% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Carcinoma, Renal Cell appearing as the primary indexed condition, and to 2 interventions - of which SU011248 is the first listed.

NCT00083889 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Connecticut, Florida.

Frequently Asked Questions

What is clinical trial NCT00083889 about?

NCT00083889 is a clinical study titled "SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma". The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).

What is the current status of trial NCT00083889?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 750 participants. The study started on 2004-08. Estimated completion is 2008-09.

What conditions does trial NCT00083889 study?

This clinical trial studies the following conditions: Carcinoma, Renal Cell.

What interventions are being tested in trial NCT00083889?

The interventions under investigation include: SU011248 (DRUG), Interferon-alfa (DRUG).

Who is sponsoring clinical trial NCT00083889?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00083889 being conducted?

This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Renal Cell

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Renal Cell

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.